Ophthalmic features of HIV associated cryptococcal meningitis in Malawian Adults: an observational study [version 1; peer review: awaiting peer review] by Ellis, J et al.
 Open Peer Review
Any reports and responses or comments on the
article can be found at the end of the article.
RESEARCH ARTICLE
Ophthalmic features of HIV associated cryptococcal meningitis
 in Malawian Adults: an observational study [version 1; peer
review: awaiting peer review]
Jayne P. Ellis ,       Kate Gaskell , Mary Peirse , Jack Gormley ,
       Newton Kalata , Philip I. Burgess , Patty Mopamboli , Chatonda A. Manda ,
       Christine A. Kiire , Ian Maccormick , Ebbie Gondwe , Sile Molloy ,
   Thomas S. Harrison , David G. Lalloo , Robert S. Heyderman 1,3
Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi
University College London Hospitals NHS Trust, London, UK
Division of Infection and Immunity, University College London, London, UK
London School of Hygiene & Tropical Medicine, London, UK
Department of Eye and Vision Science, University of Liverpool, Liverpool, UK
University of Malawi College of Medicine, Blantyre, Malawi
Oxford Eye Hospital, John Radcliffe Hospital, Oxford, UK
Institute for Infection and Immunity, St George's, University of London, London, UK
Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK
Abstract
 Cryptococcal meningitis (CM) is the commonest neurologicalBackground:
complication in patients with advanced HIV. Visual disturbance is a frequent
presenting symptom. Papilloedema is commonly reported but other
ophthalmic findings are not well described.
We performed an observational study comparing severelyMethods: 
immunocompromised HIV-infected patients with and without CM to
determine the nature and prevalence of retinal pathology attributable to CM.
70 adult patients were enrolled in Blantyre Malawi, 35 with CM and 35
HIV-infected patients without CM.
79% (19/24) of CM patients examined on day one had evidenceResults: 
of retinal abnormalities compared to 17% (6/35) of HIV-infected controls (p
<0.001). In the CM group, retinal whitening was the commonest abnormality
(50%), followed by optic disc swelling (29%), haemorrhage (25%) and
vascular abnormalities (7%). Retinal whitening was the only abnormality
observed in the comparator group (17%). In CM, there was no significant
difference between those with and without retinal abnormalities in fungal
burden (13,550 cfu/ml vs. 9,150 cfu/ml; p = 0.65), CD4 count (28 cells/µl vs.
76 cells/µl; p = 0.79) or CSF opening pressure (21cm H20 vs. 27cm H20; p
= 0.5).  There was no association between presence/absence of retinal
abnormalities and death (40% 10-week mortality vs. 26%; p = 0.6).
 Whether the presence of CM retinopathy could be used as aConclusions:
marker of disease severity warrants further investigation. The observed
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 marker of disease severity warrants further investigation. The observed
ophthalmic findings provide a descriptive framework for CM retinopathy to
be utilised in future CM studies.
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Background
Cryptococcal meningitis (CM) remains a leading cause of 
death in patients with advanced HIV, accounting for 15% of 
AIDS-related deaths in 20141. Visual disturbances associated 
with cryptococcal meningitis are common including reduced 
visual acuity, blurred vision, diplopia and photophobia. In a 
South African study of patients with HIV-associated CM due to 
Cryptococcus neoformans, 46.5% (40/86) had decreased visual 
acuity2. Visual loss was also reported frequently in CM caused 
by Cryptococcus gattii, in 82 immunocompetent patients from 
Papua New Guinea, visual loss occurred in 52.6% of survivors3. 
Visual loss may occur secondary to raised intracranial pressure 
or be due to direct fungal invasion of the optic nerve, optic 
chiasm or optic tracts4. Retinal features associated with CM have 
not been well-described. 
Intracranial hypertension occurs in up to 75% of patients with 
CM5 and papilloedema is reported to be the commonest reti-
nal finding, ranging between 33% and 48% of patients6–9. In a 
study of CM patients with catastrophic visual loss, papilloedema 
was observed in 70% (33/47)10. Other ophthalmic features 
reported to be associated with CM in case reports include: retinal 
haemorrhages6, neuroretinitis5, multi-focal choroiditis11, optic 
atrophy12, vascular tortuosity13, exudative retinal detachment14, 
cloudy vitreous15, and endophthalmitis16. To what extent these 
changes were attributable to CM rather than HIV retinopathy, 
or other opportunistic infections e.g. CMV retinitis7, is uncertain.
We performed an observational study comparing severely 
immunocompromised HIV-infected Malawian adults with and 
without CM to determine the nature and prevalence of retinal 
pathology attributable to CM. This study was nested within the 
Advancing Cryptococcal meningitis Treatment for Africa (ACTA) 
trial17.
Methods
The ACTA trial was a Phase III multi-centre randomised control-
led trial which aimed to identify the optimal treatment of HIV- 
associated CM in resource limited settings (ISRCTN45035509)17. 
HIV-infected adults with CM were randomised to one of five 
anti-fungal treatment arms and followed up for 10 weeks. The 
Queen Elizabeth Central Hospital (QECH), Blantyre, Malawi, 
was the largest recruiting centre. Patients were treated with anti- 
retroviral therapy (ART) according to national guidelines.
QECH is a large tertiary referral hospital in Southern Malawi. 
Between March 2014 and July 2015, a subset of consecu-
tive consenting adults from the ACTA trial were recruited into 
the ophthalmology sub-study. This subset comprised all ACTA 
patients who were sufficiently stable to comply with a full 
ophthalmology assessment and able to consent.
Baseline clinical and laboratory data was collected including: 
duration of ART, CD4 count using case report forms (CRFs); 
cerebrospinal fluid (CSF) opening pressure was measured using 
manometers used during lumbar puncture and quantitative cryp-
tococcal culture (QCC) was performed as described previously18. 
Dilated indirect ophthalmoscopy using a hand-held ophthal-
moscope was performed by a trained ophthalmologist. Visual 
acuity was tested using the logMAR (logarithm of the minimum 
angle of resolution) scale. Low vision was defined as a visual 
acuity less than +0.50 logMAR but equal to or better than +1.3 
logMAR.19. The team aimed to re-examine participants at day 
7, week 4 and week 10. Additional examinations however 
depended upon patient consent, clinical status and availability of 
an ophthalmologist.
From November 2015 to June 2016, 35 HIV-infected other-
wise healthy patients with CD4 <100 cells/µl were recruited by 
convenience sampling from QECH antiretroviral clinic as a 
comparator group. Exclusion criteria were: previous episode 
of CM or current symptoms or signs of meningitis. Baseline 
clinical data were collected including: CD4 count, ART use and 
co-morbidities using standardised CRFs. Visual acuity testing 
using the logMAR scale and dilated indirect ophthalmoscopy 
using a hand-held ophthalmoscope, was performed at recruitment 
only. 
Ethics: The ACTA trial protocol was approved by the London 
School of Hygiene and Tropical Medicine Research Ethics 
Committee (REC) (8854 – 5) and the University of Malawi, 
College of Medicine Research Ethics Committee (COMREC) 
(P.11/11/1149). The sub-study protocol was approved by 
COMREC (P.11/11/1149). Written informed consent was 
obtained from all participants.
Statistical analysis: Descriptive summaries were used to analyse 
the observational data as proportions or medians with ranges. We 
used SAS (version 9.3) to calculate Fisher’s exact or the Mann 
Whitney tests to compare groups. For the descriptive analysis, 
ophthalmic abnormalities were divided into 4 groups: (i) retinal 
whitening which included retinal discolouration, cotton wool 
spots, white plaques and choroidal lesions (ii) optic disc swelling 
(iii) haemorrhage and (iv) vascular abnormalities including 
vascular tortuosity and dilated vessels.
Results
46 CM patients recruited to the ACTA study were screened 
for recruitment to the ophthalmology sub-study. Eight patients 
died before an ophthalmological examination could be per-
formed, one patient was deemed too unwell, one patient was 
subsequently excluded from the ACTA trial and one patient 
was lost to follow up. 35 HIV-infected patients without 
CM were also recruited (see underlying data20).
Baseline characteristics
The median age was 35 years in both groups (range 29 – 51 in 
CM group, 23-62 in HIV-infected comparator group), 71% 
(25/35) were male in the CM group compared with 51% (18/35) 
in the HIV-infected comparator group (p = 0.06). All participants 
had advanced HIV and there was no difference in the median 
CD4 counts between groups: 28 cells/µl in the CM group vs. 
44 cells/µl in the HIV-infected comparator group (p = 0.21). 
There was no difference in the proportion of patients on ART 
between groups (16/35, 46% and 14/35, 43%, p = 0.63). 11% 
(4/35) of CM patients reported visual loss at recruitment, but on 
formal logMAR testing 39% (7/18) had evidence of reduced 
visual acuity, 2/18 (11%) were blind. Patients with CM were 
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more likely to have reduced visual acuity compared to the 
HIV-infected comparator group (39% vs. 9%, p = 0.02).
Ophthalmic signs
79% (19/24) of CM patients examined on day one had evidence 
of retinal abnormalities compared to 17% (6/35) of the HIV- 
infected controls (p <0.001) (Table 1).
82% (23/28) of CM patients examined within one week of CM 
diagnosis had evidence of retinopathy. In this first week, reti-
nal whitening was the commonest abnormality observed (14/28, 
50%), followed by optic disc swelling (8/28, 29%), haemorrhage 
(7/28, 25%), vascular abnormalities (2/28, 7%) and cloudy vit-
reous (2/28, 7%) (Table 1, Figure 1). 75% (6/8) of patients with 
optic disc swelling had raised intracranial pressure (CSF opening 
pressure > 20cm H20) and 35% (6/17) of patients with raised 
intracranial pressure had optic disc swelling. To investigate 
the relationship between retinopathy and CM disease sever-
ity, an association between the following indicators and the 
presence or absence of retinopathy (observed ≤ one week 
after CM diagnosis) was explored. There was no significant 
difference in fungal burden (median QCC: 13,550 cfu/ml vs. 
Table 1. Prevalence of retinal pathology in Cryptococcal Meningitis (CM) patients.
Time of 
fundoscopy
Abnormal 
fundoscopy 
N (%)
Retinal 
whitening 
N (%)
Optic disc 
swelling 
N (%)
Retinal 
haemorrhage 
N (%)
Vascular 
abnormality 
N (%)
Other* 
N (%)
CM Week 1 23/28 (82) 14/28 (50) 8/28 (29) 7/28 (25) 2/28 (7) 2/28 (7)
CM Week 4 – 10 8/13 (61) 6/13 (46) 1/13 (8) 1/13 (8) 1/13 (8) 0/7 (0)
HIV-infected 
controls
6/35 (17) 6/35 (17) 0/35 (0) 0/35 (0) 0/35 (0) 0/35 (0)
Other* = cloudy vitreous.
Figure 1: Retinal photographs taken from patients with HIV associated cryptococcal meningitis. 1a shows localised vascular tortuosity 
(blue arrow) with associated haemorrhage (green arrow). 1b shows a cotton wool spot (blue arrow). 1c shows swelling of the nasal optic disc 
margin (blue arrow). 1d shows vascular engorgement and focal tortuosity (blue arrows). 1e shows atypical retinal whitening (blue arrow) and 
nasal disc swelling (green arrow). 1f shows a white centred haemorrhage (blue arrow). 
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9,150 cfu/ml p = 0.65) or CD4 count (median CD4 count: 
28 cells/µl vs. 76 cells/µl, p = 0.79). There was no association 
between CSF opening pressure at diagnosis (21cm H20 vs. 27cm 
H20; p = 0.5), ART use (12/23, 52% vs. 2/5, 40%; p = 1.0) or 
baseline haemoglobin (11.2g/dL vs. 11.1g/dL; p = 0.4) and the 
presence of retinal abnormalities. There was no association 
between presence of retinal abnormalities and death (40% 
10-week mortality vs. 26%; p = 0.6).
In contrast to the range of retinal signs seen in the CM 
patients, retinal whitening was the only abnormality observed 
in the HIV-infected comparator group (6/35, 17%; Table 1). 
A subset of CM patients (13/35) had indirect ophthalmos-
copy performed between 4–10 weeks after diagnosis and 
commencement of anti-fungal therapy. Six of these patients 
had undergone an earlier ophthalmological examination during 
the first week and seven patients were examined for the first 
time between week 4 – 10. Some of these patients (8/13, 61%) 
had evidence of retinopathy. Retinal whitening remained the 
most frequent abnormality observed (6/13, 46%). Optic disc 
swelling, retinal haemorrhages and vascular abnormalities 
were seen in one patient each (8%). Of the six patients who had 
previously undergone ophthalmic examination during week one 
of their CM episode, two patients (33%) had complete resolution 
of their retinopathy, two patients (33%) had evidence of persist-
ent retinal whitening, one patient (17%) had persistent mild optic 
disc swelling and one patient (17%) had a normal examination 
at both time points.
Discussion
Our observational study highlights the range and relative fre-
quency of ophthalmic abnormalities that are associated with 
acute CM. Retinal whitening was the most common abnormality 
observed, followed by optic disc swelling, haemorrhage and 
vascular abnormalities; these features have each been docu-
mented previously in case reports7,9,10. Among CM patients who 
were examined within one week of CM diagnosis, optic disc 
swelling was observed in 29% which is in line with other CM 
case series (range 32.5% – 37.5%)7–9. Previous CM studies have 
clearly demonstrated an association between the presence of 
optic disc swelling and raised ICP21. Although most patients in 
our cohort with optic disc swelling had raised intracranial pres-
sure, importantly only a third of patients with raised intracranial 
pressure had optic disc swelling.
Retinal whitening may be due to oncotic cell swelling in response 
to reduced perfusion or occlusion caused by microthrombi22, 
both of these mechanisms may be important in patients with CM 
due to the pro-inflammatory, vasculitic nature of the disease23,24. 
However, retinal whitening was also observed in the HIV-
infected comparator group and has previously been described in 
association with HIV retinopathy25. Indeed, retinal whitening 
is observed in a range of retinal vascular disorders including 
cerebral malaria, retinal arterial occlusion and retinal vein 
occlusion22. In some patients retinal whitening may have pre- 
dated the onset of CM.
The highest prevalence (82%) of retinopathy in CM was observed 
during the first week after diagnosis. In a subset of patients 
examined between week 4–10, fewer (61%) had evidence of 
retinopathy. The resolution of the ophthalmic features associated 
with CM has not been reported previously6–8,13 and therefore 
needs to be investigated in larger cohorts.
Although patients with evidence of CM retinopathy had lower 
median CD4 counts and higher fungal burdens, our study 
was underpowered to detect a clear association with these 
features or indeed death. In a study of 80 HIV-associated CM 
cases from Rwanda, there was a non-significant trend towards 
shorter median survival times in patients with cotton wool 
spots (102 days) compared to those without cotton wool spots 
(186 days)7. Future larger studies of CM should determine whether 
the retinal abnormalities associated with CM could be used as a 
marker of disease severity.
The strength of this study was that it was nested within a 
randomized controlled trial which provided standardized data col-
lection, diagnosis and treatment. All patients were examined by 
a trained ophthalmologist and in contrast to other case series, we 
had a severely immunocompromised HIV-infected comparator 
group. This study was limited by the relatively small number 
of participants, many of whom were only examined at a single 
time point. Although the cohort characteristics were similar to 
the main ACTA trial15, we have inevitably sampled patients 
with less severe CM, who were able to tolerate and consent to 
an ophthalmological assessment.
Conclusion
Optic disc swelling, retinal haemorrhages and vascular abnor-
malities are commonly observed in patients with acute CM, with 
the highest prevalence in the first week following diagnosis. 
Whether the presence of CM retinopathy could be used as 
a marker of CM severity warrants further investigation. The 
observed ophthalmic findings provide a descriptive framework 
for CM retinopathy to be utilised in future CM studies.
Data availability
Figshare: Ophthalmic features and clinical data of HIV-infected 
Malawian adults with and without cryptococcal meningitis. 
https://doi.org/10.6084/m9.figshare.808227520
This project contains the following underlying data:
•    RDS-SPRN-00282 resubmission.xlsx (Spreadsheet con-
taining demographic, clinical, lab and ophthal data for all 
participants)
Data are available under the terms of the Creative Commons 
Zero “No rights reserved” data waiver (CC0 1.0 Public domain 
dedication).
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